CN111514213A

CN111514213A - Antiviral traditional Chinese medicine composition for respiratory system

Info

Publication number: CN111514213A
Application number: CN202010248410.3A
Authority: CN
Inventors: 杜成强
Original assignee: Tsing Hua De Ren Xi'an Happiness Pharmaceutical Co ltd
Current assignee: Tsing Hua De Ren Xi'an Happiness Pharmaceutical Co ltd
Priority date: 2020-04-01
Filing date: 2020-04-01
Publication date: 2020-08-11

Abstract

The invention relates to an antiviral traditional Chinese medicine composition for a respiratory system, wherein the traditional Chinese medicine composition thermitis ning mixture has an obvious treatment effect on respiratory system infectious mouse models induced by influenza virus, streptococcus pneumoniae and beta hemolytic streptococcus, the effect of the traditional Chinese medicine composition under clinical use dosage is equivalent to that of duffy and amoxicillin, and a new thought is provided for clinical treatment of novel coronavirus pneumonia. The technical scheme adopted by the invention is as follows: a use of Reyanning in treating influenza virus infection with strain H1N1/FM1 is provided. A use of Reyanning in treating Streptococcus pneumoniae infection is provided. A use of thermitis preparation for treating beta hemolytic streptococcus infection is provided. The dose of the mixture of thermitis and tannin is 20mL/kg, 10mL/kg or 5 mL/kg.

Description

Antiviral traditional Chinese medicine composition for respiratory system

The technical field is as follows:

the invention relates to application of a traditional Chinese medicine, in particular to an antiviral traditional Chinese medicine composition for a respiratory system.

Background art:

viral and bacterial infections are common causes of acute respiratory diseases. Viruses causing respiratory infections include coronavirus, influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, and the like. The pathogenic bacteria causing respiratory tract bacterial infection are many, and streptococcus pneumoniae, beta hemolytic streptococcus, pseudomonas aeruginosa, staphylococcus aureus and the like are common. The acute respiratory infection caused by virus and bacterial infection is clinically mainly manifested by nasal obstruction, running nose, sore throat, dry cough and other upper respiratory infection symptoms, when the virus spreads to the lower respiratory tract, capillary bronchitis and interstitial pneumonia can be caused, the infectivity is high, the spread is rapid, the epidemic is easy to occur, and the harmfulness is large. At present, the number of specific chemical drugs for resisting respiratory infectious diseases is limited, and the problems of drug resistance, adverse reaction and the like exist, so that the search for the effect of Chinese patent drugs in the treatment of infectious respiratory diseases is particularly necessary.

The mixture for treating heat inflammation is a variety in Chinese pharmacopoeia, consists of dandelion, giant knotweed rhizome, patrinia scabiosaefolia and barbed skullcap herb, has the functions of clearing heat and removing toxicity, and is used for treating wind-heat type common cold, fever, swollen and sore throat, bitter taste and dry throat, cough with yellow phlegm, yellow urine and constipation caused by wind-heat type common cold and internal stagnation of fire; suppurative tonsillitis, acute pharyngitis, acute bronchitis, and simple pneumonia. The product has better effects on treating respiratory diseases such as upper respiratory tract infection, cold and fever, acute pharyngitis, pneumonia and the like, is more reported in the aspect of treating hand-foot-mouth diseases, and shows obvious antiviral effect.

The invention content is as follows:

the invention aims to provide an antiviral traditional Chinese medicine composition for a respiratory system, the traditional Chinese medicine composition, namely the therminingine, has obvious treatment effect on respiratory system infectious mouse models induced by influenza virus, streptococcus pneumoniae and beta hemolytic streptococcus, the effect is equivalent to that of duffy and amoxicillin under clinical use dosage, and a new idea is provided for clinical treatment of novel coronavirus pneumonia.

In order to achieve the purpose, the invention adopts the technical scheme that:

an antiviral traditional Chinese medicine composition for respiratory system, which is characterized in that: the Chinese medicinal composition is REYANNING.

Application of Reyanning in respiratory system antivirus

A use of Reyanning in treating influenza virus infection with strain H1N1/FM1 is provided.

A use of Reyanning in treating Streptococcus pneumoniae infection is provided.

A use of thermitis preparation for treating beta hemolytic streptococcus infection is provided.

Reyanning is a mixture.

The Reyanning is tablet, granule, capsule or powder.

The dosage of the mixture of the thermite and the tannin is 5mL/kg-20 mL/kg.

The dose of the mixture of thermitis and tannin is 20mL/kg, 10mL/kg or 5 mL/kg.

Compared with the prior art, the invention has the following advantages and effects:

the lung indexes of mice with pathogenic and toxic pneumonia of influenza virus H1N1/FM1 strains can be obviously reduced by three dose groups of the mixture for treating the hepatitis B, and compared with a model control group, the mixture for treating the hepatitis B has obvious difference (P is less than 0.01 and P is less than 0.05), the inhibition rate of the lung indexes of the dose groups in the mixture for treating the hepatitis B is 61.98 percent, and the inhibition rate of the lung indexes of the dose groups in the mixture for treating the hepatitis B is equivalent to the inhibition rate of the lung indexes of a Tamiflu control group of 69.; the mixture of the Reyanning can reduce the death rate of mice, and the medium and small dose groups can prolong the survival days of the mice, and have statistical difference compared with a model control group (P < 0.05). The large and medium dose group of the mixture of the Reyanning can obviously reduce the lung index of the mice with the bacterial pneumonia caused by the streptococcus pneumoniae, and has significant difference (P <0.01) compared with a model control group; the lung index inhibition rate of the large-dose group of the mixture for treating the enteritis is 49.56 percent and is higher than that of the large-dose group of the amoxicillin by 48.89 percent. The three dose groups of the mixture for treating the hepatitis B can reduce the death rate of mice with bacterial respiratory tract infection caused by the streptococcus B hemolyticus, the medium and small dose groups can prolong the survival days of the mice, and the statistical difference is realized when compared with a model control group (P is less than 0.01, and P is less than 0.05). The antipyretic mixture has obvious treatment effect on respiratory system infectious mouse models induced by influenza virus, streptococcus pneumoniae and beta hemolytic streptococcus, has the effect equivalent to that of duffy and amoxicillin under clinical use dosage, and provides a new idea for clinical treatment of novel coronavirus pneumonia.

Description of the drawings:

FIG. 1 shows the effect of a mixture of thermitis preparations on the pulmonary index and the pulmonary index inhibition rate of a mouse pneumonia model caused by influenza virus H1N1/FM1 strain (N ═ 1%0). Wherein, a lung index; and B, lung index inhibition rate. Comparison with normal control group:^##P<0.01; comparison with model control group:^*P<0.05，^**P<0.01。

FIG. 2 shows the effect of a mixture of thermingning drugs on the mortality, mortality protection, survival days, and life prolongation of mice induced by influenza virus strain H1N1/FM1 (N20). Wherein, a mortality, mortality protection; b, average survival days; c rate of life prolongation. Comparison with model control group:^*P<0.05，^**P<0.01。

FIG. 3 shows the effect of Reyanning mixture on the pulmonary index and the inhibition rate of pulmonary index in a mouse model of pneumonia caused by Streptococcus pneumoniae (n 10). Wherein, a lung index; and B, lung index inhibition rate. Comparison with normal control group:^##P<0.01; comparison with model control group:^*P<0.05，^**P<0.01。

FIG. 4 shows the effect of Reyanning mixture on the mortality, mortality protection, survival days and life prolongation of mice with beta hemolytic Streptococcus (n 20). Wherein, a mortality, mortality protection; b mean survival days; c rate of life prolongation. Comparison with model control group:^*P<0.05，^**P<0.01。

FIG. 5 shows the effect of Reyanning mixture on the pathomorphology of pharyngeal tissue in rat pharyngitis model caused by beta hemolytic streptococcus (n ═ 10). Wherein, A is macroscopic pathology; and B, under-mirror pathology. 1 normal control group; 2 model control group; 3 amoxicillin group; 4 Reyanning mixture high dose group; 5 in-mixture dosage group of Reyanning; 6 Reyanning mixture low dose group. Comparison with normal control group:^##P<0.01; comparison with model control group:^*P<0.05，^**P<0.01。

the specific implementation mode is as follows:

the present invention will be described in detail with reference to specific embodiments. These examples are intended to illustrate the invention and are not intended to limit the scope of the invention. The implementation conditions used in the examples can be further adjusted according to the specific experimental environment, and the implementation conditions not mentioned are generally the conditions in routine experiments.

Infectious respiratory disease patients are increasingly paid attention in clinical work, and a series of problems of pathogen gene variation, cross infection, flora imbalance, infection difficult to cure and the like occur due to wide application of society, host factors, immune inhibitors and antibiotics. Infectious respiratory disease pathogens induce increased expression of antibodies and cytokines, thereby inducing a series of inflammatory responses in the body. When the body is infected with pathogens, the pathogens entering the respiratory system grow and multiply rapidly and cause tissue organ allergies, such as alveolar septal capillary dilation, increased permeability, and massive exudation of serous fluid and fibrinogen, even spreading to adjacent lung tissues. The pneumonia caused by bacterial invasion is mainly characterized by a large amount of neutrophil infiltration, the secretion of proinflammatory factors is increased, and the bronchial epithelium and lung tissues can obviously undergo necrosis and hemorrhage in severe cases. Pneumonia caused by influenza virus and adenovirus can cause the exudation in the alveolar cavity to be obvious, and the alveolar cavity is formed with a transparent membrane, and bronchial epithelial cells are proliferated, even multinuclear giant cells are formed.

In the face of the serious drug resistance and gene mutation of many old infectious causes and the pressure of a large number of newly discovered infectious diseases, the importance of infectious animal models is widely regarded in China in recent years. Viral infection and bacterial infection respiratory system disease models have been established in various strains of over ten animals such as rats, mice, rabbits, and the like^[11-16]The infection models play an important role in controlling infectious diseases in China, researching the pathogenesis and the immune tolerance mechanism of infectious disease pathogens, screening therapeutic drugs, observing the curative effect of the drugs and evaluating the protective effect of vaccines.

The prescription of the mixture for treating the heat-fire-toxin mainly clears away heat and toxic materials, and the dandelion in the prescription clears away heat and toxic materials, eliminates carbuncle and stagnation, promotes diuresis, relieves jaundice, drenches and relieves pain; herba Patriniae has effects of clearing heat, removing pathogenic accumulation, inducing diuresis, relieving swelling, removing blood stasis, and expelling pus; the barbed skullcap herb has the effects of clearing away heat and toxic materials, relieving swelling and pain, dispelling wind and dredging collaterals, and promoting qi circulation and inducing diuresis; giant knotweed rhizome has the effects of dispelling wind, clearing heat, relieving cough and reducing sputum, and is used for treating dysphoria due to high fever and quenching thirst. Modern pharmacological research shows that the four Chinese medicines in the prescription contain rhubarb anthraquinone, caffeic acid, flavone and other chemical components, and have the functions of resisting inflammation, resisting virus, resisting bacteria and raising immunityBody defense ability, and blood circulation promoting effects^[17-21]It is suitable for the pathogenesis of infectious respiratory system diseases in traditional Chinese medicine and the pathological characteristics of western medicine.

The invention relates to an application of Yanning mixture in treating respiratory system infectious inflammation, which specifically comprises the following applications:

the application of the mixture of thermitis and tannin in treating the infection of influenza virus strain H1N1/FM 1. The dose of the mixture of thermitis and tannin is 20mL/kg, 10mL/kg or 5 mL/kg. The dosage of the mixture for treating pyretic inflammation is 50ml per adult.

The use of a mixture of thermitis treatments for streptococcus pneumoniae infection. The dosage of the mixture of the thermite and the tannin is 20mL/kg or 10 mL/kg. The dosage of the mixture for treating pyretic inflammation is 50ml per adult.

The use of a mixture of thermitis and tannin for the treatment of beta hemolytic streptococcal infection. The dose of the mixture of thermitis and tannin is 20mL/kg, 10mL/kg or 5 mL/kg. The dosage of the mixture for treating pyretic inflammation is 50ml per adult.

Experimental example:

the drug effect of the mixture of the Reyanning agent on a respiratory system infectious mouse model induced by influenza virus, streptococcus pneumoniae and beta hemolytic streptococcus is observed. The method comprises the steps of designing three dosage groups of 20mL/kg, 10mL/kg and 5mL/kg of a thermitis mixture, respectively carrying out five experiments of treating the influenza virus H1N1/FM1 strain-induced mouse pneumonia model by the thermitis mixture, protecting the influenza virus H1N1/FM1 strain-induced mouse death, treating the streptococcus pneumoniae-induced mouse pneumonia model, protecting the beta hemolytic streptococcus-induced mouse death and treating the beta hemolytic streptococcus-induced rat acute pharyngitis model, measuring lung indexes of animals in each group, recording the death number of the animals, and calculating the death rate, the death protection rate and the life prolonging rate.

1 test Material

1.1 animal ICR mouse, weight 16 + -1 g, sex half each, purchased from Beijing vitamin Tonglihua laboratory animal technology Co., Ltd, license number: SCXK (Jing) 2014-. SD rats weighing 220 + -20 g, half male and female, purchased from Beijing Wittingli laboratory animal technology Limited, license number: SCXK (Jing) 2014-. The animals were all kept in ABSL-2 laboratory, institute of Chinese medicine, academy of traditional Chinese medicine, at room temperature (22 + -1) deg.C and relative humidity (55 + -15)%. The experiment is approved by the ethical committee of the institute of traditional Chinese medicine of the Chinese academy of traditional Chinese medicine, and is numbered: death protection experiment 20190217, therapeutic efficacy experiment 20190218. 1.2 strains influenza A virus mouse lung adapted H1N1/FM1 strain, streptococcus pneumoniae, beta hemolytic streptococcus, all purchased from China disease prevention and control center, and were routinely passaged by ABSL-2 laboratories of this institute, and stored at-80 ℃ for future use.

1.3 medicine

Reyanning mixture (both of them refer to

Thermitis mixture) was provided by qinghua de man sienna happy pharmacy limited, lot No. 190620, specification: 100 ml/bottle oseltamivir phosphate capsule (tamiflu), bessel luxury meyer switzerland, roche limited, shanghai, manufactured by roche limited, production lot No. M1050, lot No. sh0079, amoxicillin dispersible tablets were manufactured by haikou pharmaceutical factory limited, lot No. 190603, specification: 0.25g × 24 tablets.

1.4 major reagents & instruments biosafety cabinet, model a2 MSC1.2, Thermo corporation, usa; CO 2₂Incubator, Thermo-371, Thermo corporation, U.S.A.; YP/0001 type electronic balance (limited Shanghai Yueping scientific instruments); an electronic balance of the AR1140 model (Chaus corporation, usa).

2 test method

2.1 dosage design the daily dosage of the mixture for treating the hepatitis is 50ml for adults, 5ml/kg, 10ml/kg and 20ml/kg (respectively equal to 1/2, 1 and 2 times of the clinical dosage) are adopted for experimental mice, and the mixture for treating the hepatitis is administrated by intragastric administration for 1 time per day during experiments. The daily dosage of the clinical Tamiflu for adults is 150mg, 2 times a day, the equivalent dosage converted into a mouse is 25mg/kg, and the Damiflu is administrated by intragastric administration according to 0.2ml/10g and 1 time a day. The daily dosage of amoxicillin for clinical adults is 2g/60kg, the equivalent dosage converted into mice is 330mg/kg, and the amoxicillin is infused into the stomach according to 0.2mL/10g for 1 time per day; the equivalent dose of rats is 150mg/kg, and the rats are gavaged with 1mL/100g of the traditional Chinese medicine composition 1 time a day.

2.2 Molding, grouping and administration

2.2.1 therapeutic Effect of Reyanning mixture on mouse pneumonia model caused by influenza virus H1N1/FM1 strain: 60 ICR mice are taken and randomly divided into 6 groups according to the weight, wherein the 6 groups are respectively a normal control group, a model control group, a tamiflu control group and a mixture of the Reyanning agent, and the three groups comprise a large dose group, a middle dose group and a small dose group, and each group comprises 10 mice. Except for the normal control group, mice were lightly anesthetized with ether and 15 LD were administered₅₀Influenza virus fluid (strain H1N1/FM 1) was infected by nasal drops of 35. mu.L each, resulting in a viral pneumonia model. The administration is started on the day of infection, the gavage is carried out for 1 time every day for 4 days according to the proportion of 0.2mL/10g, and the gavage is carried out on a normal control group and a model control group by distilled water under the same condition.

2.2.2 protective action of Reyanning cocktail on death of mice by influenza virus H1N1/FM1 strain: the ICR mice are randomly divided into 5 groups according to body weight, and the three groups are respectively a model control group, a tamiflu control group and a thermite mixture, and each group comprises 20 mice. Mice in each group were lightly anesthetized with ether and treated with 2 LD₅₀Influenza virus liquid (H1N1/FM1 strain) was infected by nasal drops of 30. mu.L each. Administration was started on the day of infection, mice in each group were gazed at 0.2mL/10g each time, 1 time per day for 5 consecutive days, and the mice in the model control group were gazed with distilled water under the same conditions to observe the death of the animals within 2 weeks after infection.

2.2.3 therapeutic action of Reyanning mixture on mouse pneumonia model caused by streptococcus pneumoniae: 60 ICR mice are taken and randomly divided into 6 groups according to body weight, wherein the groups are three dose groups of a normal control group, a model control group, an amoxicillin capsule control group and a thermite mixture, and each group comprises 10 mice. Except for a normal control group, mice in each group were lightly anesthetized with diethyl ether and infected with streptococcus pneumoniae bacterial solution by nasal drip, each group was infected with 35 μ L, and each administration group was administered by intragastric administration at 1 hour after infection, 0.2mL/10g, 1 time per day, and continuous administration for 4 days. The normal control group and the model control group were given distilled water under the same conditions.

2.2.4 protective action of Reyanning mixture on mouse death by beta hemolytic streptococci: 100 ICR mice are taken and randomly divided into 5 groups according to body weight, and the groups are respectively a modelThree dosage groups of type control group, amoxicillin control group and thermite combination agent, wherein each group comprises 20 administration groups, each administration group is administered by intragastric administration with 0.2mL/10g, 1 time per day for 5 consecutive days, the model control group is administered with distilled water under the same condition, and each group of animals is injected with 3 × 10 in abdominal cavity on day 3⁸Each strain was contained in a volume of 0.2 mL/strain. Animals were observed daily for 7 days of mortality following infection.

2.2.5 therapeutic action of Reyanning mixture on model of acute pharyngitis in rats caused by beta hemolytic streptococcus, selecting 60 SD rats, randomly dividing into 6 groups according to body weight, respectively comprising blank control group, model control group, amoxicillin control group and Reyanning mixture, wherein each group comprises 10 rats, except blank control group, opening oral cavity of rat with sterilized hemostatic forceps to expose maxillary mucosa, sucking 3 × 10 with syringe to obtain oral cavity with 3 ×⁸The nasopharyngeal mucosa is pricked with the bacterial liquid of the B-type hemolytic streptococcus with the concentration of CFU/mL in the horizontal direction, the bacterial liquid is injected, the operation degree is to have slight punctate bleeding, 0.15 mL/mouse, and the physiological saline is injected into a blank control group under the same condition. 1h after infection, each animal was gavaged 1mL/100g for 3 consecutive days 1 time per day, and distilled water was given to the blank control group and the model control group under the same conditions.

2.3 detection of indicators

2.3.1 organ index the body mass of the mice was weighed, the mice were sacrificed by cervical spine, the lungs were peeled off, the mass was weighed, and the lung index inhibition rate were calculated.

Lung index ═ lung wet weight (g)/body mass (g);

the lung index inhibition rate is (average lung index in virus group-average lung index in experimental group)/(average lung index in virus group-average lung index in normal group) × 100%.

2.3.2 following infection, the time to death of the animals was recorded and the average number of days to live and the rate of life extension were calculated for each group of mice.

Life extension rate ═ average days to live in the administration group-average days to live in the model control group)/average days to live in the model control group × 100%;

2.3.3 record the mortality of the animals within 14d after infection and calculate the mortality, mortality protection according to the following formula.

Mortality rate is the number of deaths/total number of animals x 100%;

mortality protection rate ═ (mortality of model control group-mortality of dosing group)/mortality of model control group × 100%;

2.3.4 pathological morphology, and the pathological degree of nasopharyngeal mucosa of the rat is observed to score pharyngeal signs. Pharyngeal tissues were taken for HE staining and pathologically examined under an optical microscope.

Visual evaluation scoring standard for throat signs:

"-": no red swelling and no yellow mucus were observed on the throat mucosa of the rat, and the pharyngeal tissue structure was normal.

"+": the mucous membrane tissue of the throat of the rat has obvious red swelling, no obvious congestion and blood stasis, light yellowish mucus and no purulent substance.

"++": the mucous membrane tissue of the throat of the rat is slightly congested, the postpharyngeal part is slightly red and swollen, yellow mucus is formed, and obvious purulent substances are not seen.

"+++": the mucous membrane tissue of the throat of the rat has obvious congestion, congestion and obvious yellow mucus, the postpharyngeal portion has yellow purulent substances, and the mucous membrane tissue of the pharyngeal portion is thick.

And (3) observation and scoring standard under a throat sign mirror:

"-": no thickening of pharyngeal mucosa epithelium, no blood stasis and bleeding under the skin, no inflammatory edema and normal pharyngeal tissue structure are observed in the rats.

"+": no thickening of pharyngeal mucosa epithelial tissue, no inflammation, no swelling and slight blood stasis of subcutaneous tissues of rats are observed.

"++": the mucosal tissue of the throat of a rat is slightly thickened in sections, and the hypodermis of the rat is slightly inflamed and edematous, and takes eosinophilic cells as main components.

"+++": the mucous epithelium of the throat mucosa tissue of the rat has obvious thickening, hyperplasia and hyperkeratosis (segmental), a large amount of neutral lobular nucleus inflammatory cells are mainly infiltrated under the skin, and the rat has mast cells, lymphocytes, a small amount of plasma cells and eosinophilic cells, and a muscle layer has a large amount of bleeding and edema.

"++++": the hyperkeratosis of the throat of a rat, the epithelium of a mucous membrane tissue is thickened, the arrangement of epithelial cells is disordered, and apoptotic cells are proliferated to form spiky processes; there are lots of neutral lobular nucleus cells and broken cells with different sizes in the upper and lower skin, and there is infiltration of lymph, mast cells, plasma cells and other inflammatory cells, and there is a lot of bleeding and extravasated blood in the subcutaneous tissue, and there is infiltration of many inflammatory cells. The pathological changes are more diffuse and heavier.

2.4 statistical processing data conforming to normal distribution is represented by X + -s, and is processed by SPSS17.0 statistical software, wherein t test is adopted when variance is uniform, and X is adopted when variance is not uniform²Inspection, P<0.05 indicates a statistical difference, P<0.01 indicates a significant statistical difference.

3 results

3.1 therapeutic action of mixture of Reyanning on pneumonia of mice model caused by influenza virus H1N1/FM1 strain after mice are infected by influenza A H1N1 virus FM1 strain, the pulmonary index of the mice is obviously increased, and the pulmonary index is obviously different from that of a normal control group (P is less than 0.01); after 4 days of therapeutic administration of the mixture of Reyanning, the pulmonary index of the three dose groups is obviously reduced, and compared with the model control group, the pulmonary index of the three dose groups has significant difference (P <0.01 and P <0.05), and the result is shown in a figure 1-A. The lung index inhibition rate of the dose group in the thermitis-ning mixture is 61.98 percent, and the effect is equivalent to that of 69.25 percent of the lung index inhibition rate of the tamiflu control group, and the result is shown in a figure 1-B.

3.2 protection of drug against mouse death caused by influenza virus H1N1/FM1 strain in 2 weeks after infection of mouse with influenza A H1N1 strain FM1, the death rate of model group animal is 100%; the mortality rate of mice was reduced in all three dose groups after 5 days of therapeutic administration of the combination of antipyretics, and the results are shown in fig. 2-a. The average survival days of the mice can be prolonged by the medium and small doses of the mixture of the Reyanning drug, the statistical difference is generated when the average survival days of the mice are compared with a model control group (P is less than 0.05), the life prolonging rate reaches 19.63 percent and 18.40 percent, and the results are shown in a figure 2-B and a figure 2-C.

3.3 therapeutic action of the drug on a mouse pneumonia model caused by streptococcus pneumoniae, after a mouse is infected by streptococcus pneumoniae, the lung index of the mouse is obviously increased, and the lung index is obviously different from that of a normal control group (P is less than 0.01); after 4 days of administration of the mixture of the propyrotis and the tannin, the lung index of the large and medium dose groups is obviously reduced, and the lung index is obviously different from that of the model control group (P <0.01), and the result is shown in a figure 3-A. The lung index inhibition rates of the large and medium dose groups of the mixture for treating the hepatitis are 49.56% and 33.26% respectively, and the lung index inhibition rate of the large dose group is higher than that of the amoxicillin control group (48.89%), and the result is shown in a figure 3-B.

3.4 protective action of drug on mouse death caused by beta hemolytic streptococcus, the mortality of the model control group is 100% after the mouse is infected with the beta hemolytic streptococcus; the mortality rate of the mice in the three dose groups is obviously reduced after the curative application of the mixture for 5 days, wherein the mortality protection rate of the mice in the middle dose group reaches 30 percent, and the results are shown in a figure 4-A compared with a model with a significant difference (P < 0.05). The mean survival days of the mice can be obviously prolonged by the medium and small dose groups of the mixture of the Reyanning, and compared with a model control group, the average survival days of the mice have significant differences (P is less than 0.01, and P is less than 0.05), the life prolonging rate reaches 106.45 percent and 77.42 percent, and the results are shown in figures 4-B and 4-C.

3.5 therapeutic action of the drug on the model of acute pharyngitis caused by beta hemolytic streptococcus, after injection of the beta hemolytic streptococcus to infect nasopharyngeal mucosa of rats, pharyngeal tissues are obviously congested and inflamed, pharyngeal epithelial tissue lesion is seriously observed under a mirror and is accompanied with apoptosis, significant difference (P <0.01) is provided compared with a blank group, thermoyanning mixture is given for dry prognosis, pharyngeal red and swollen of rats in three dose groups can be obviously subsided under visual observation, significant difference (P <0.01, P <0.05) is provided compared with the model group, and the result is shown in figure 5-A; the small dose group of the mixture for treating the hepatitis can obviously improve the pharyngeal lesion by observing under a mirror, and has significant difference (P is less than 0.01) compared with a model group, and the result is shown in a figure 5-B.

Infectious respiratory diseases can cause changes such as pulmonary edema, inflammatory exudation and hemorrhage, which all increase the weight of the lung and thus lead to an increase in the lung index, so the severity of lung lesions is usually expressed in terms of the size of the lung index value. In the experiment, a mouse infection H1N1/FM1 influenza virus pneumonia model, a mouse pneumonia model caused by streptococcus pneumoniae, a rat acute pharyngitis model caused by beta hemolytic streptococcus and a mouse death model caused by beta hemolytic streptococcus are established, and the lung index is used as an observation index, so that the treatment effect of the mixture of the thermitis and the tranquilizer on infectious respiratory diseases is determined. The results show that: the mixture has remarkable treatment and protection effects on mouse pneumonia model caused by H1N1/FM1 influenza virus, can reduce death rate and prolong survival time; the Reyanning mixture has obvious treatment and protection effects on mouse pneumonia and pharyngitis models caused by streptococcus pneumoniae and beta hemolytic streptococcus, can relieve inflammatory reaction of lung tissues, reduce mortality, prolong survival time and improve throat tissue lesions of rats, and has the same effects of treating respiratory system diseases caused by virus infection and bacterial infection as those of Duffy and amoxicillin under clinical application dosage. Meanwhile, the Reyanning mixture has obvious advantages in the aspects of improving the overall state of animals, such as body weight, hair, activity and the like when being used for treating infectious diseases. The effect of the medium-dose group is better than that of the large-dose group, which is observed in the experiment because the absorption capacity of the medicine in the gastrointestinal tract is reduced due to mild diarrhea of part of animals in the large-dose group during the experiment.

The research successfully prepares infectious inflammation models of respiratory systems of rats and mice by using H1N1/FM1 influenza virus, streptococcus pneumoniae and beta hemolytic streptococcus on animal models, evaluates the pharmacodynamic action of the mixture of the thermitis and the Ningning on 5 animal models by therapeutic administration, provides experimental basis for the clinical application of the mixture of the thermitis and the Ningning, provides a methodology reference for researching and developing traditional Chinese medicine preparations for preventing and treating respiratory diseases such as influenza and the like, and provides a new idea for the clinical treatment of novel coronavirus pneumonia.

Claims

1. An antiviral traditional Chinese medicine composition for respiratory system, which is characterized in that: the Chinese medicinal composition is Reyanning.

2. A use of Reyanning in respiratory system for resisting virus is provided.

3. The use of a thermionic compound according to claim 2 for the treatment of infection by influenza virus strain H1N1/FM 1.

4. A thermionic composition according to claim 2 for use in the treatment of streptococcus pneumoniae infection.

5. Use of a thermionic preparation according to claim 2 for the treatment of b hemolytic streptococcal infection.

6. Use according to claim 2, 3, 4 or 5, characterized in that: reyanning is a mixture.

7. Use according to claim 2, 3, 4 or 5, characterized in that: the Reyanning is tablet, granule, capsule or powder.

8. Use according to claim 2, 3, 4 or 5, characterized in that: the dosage of the mixture of the thermite and the tannin is 5mL/kg-20 mL/kg.

9. Use according to claim 8, characterized in that: the dose of the mixture of thermitis and tannin is 20mL/kg, 10mL/kg or 5 mL/kg.